National Center of Competence
in Research, RNA & Disease

Promising Next-Generation SARS-CoV-2 Live Vaccine Demonstrates Remarkable Safety, Protection, and Immunity Profile in Pre-Clinical Studies

Overview of mutations introduced into the SARS-CoV-2 genome to generate LAVs. Fragments 4, 5, 7 and 8 were modified to generate one-to-stop codons. Specific changes are indicated for each fragment. OTS-206 also has additional Nsp1 mutations (K164A/H165A) and deletions of ORF6 to ORF8. OTS-228 is additionally missing the PCS.

Rocketvax News
The next-generation live-attenuated vaccine, named OTS-228, has demonstrated significant safety and efficacy in pre-clinical studies, marking a hopeful advancement in the fight against COVID-19. Developed by researchers from Institute of Virology and Immunology (IVI) Bern, Switzerland and the Friedrich-Loeffler-Institute on the Isle of Riems, Germany on behalf of the Swiss biotech company Rocketvax AG a subsidiary of Swiss Rockets AG, this next-generation vaccine aims to provide enhanced protection against emerging SARS-CoV-2 variants and reduce transmission.

Read the Full News on the RocketVax Website

Read the Corresponding Publication in Nature Microbiology (Open Access)

Website Thiel Lab

Figure from Schön, Barut, Trüeb et al (2024) Nat Microbiol published under a CC BY 4.0 license.
 

Back